Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U10CA031946 | U.S. NIH Grant/Contract | View source | |
| CDR0000491313 | Registry Identifier | NCI Physician Data Query |
Not provided
Not provided
Not provided
Poor accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.
OBJECTIVES:
OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| immunoenzyme technique | Other |
| ||
| laboratory biomarker analysis |
| Measure | Description | Time Frame |
|---|---|---|
| Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low) | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of biomarker expression level on overall survival | Up to 10 years |
Not provided
DISEASE CHARACTERISTICS:
Diagnosis of malignant mesothelioma
Must have received treatment with vatalanib on protocol CALGB-30107
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Patients previously enrolled on CALGB-30107 diagnosed with malignant mesothelioma.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert A. Kratzke, MD | Masonic Cancer Center, University of Minnesota | Study Chair |
Not provided
Not provided
Not provided
Not provided
Not provided
Samples retained from patients participating on CALGB-30107.
|
| ID | Term |
|---|---|
| D000086002 | Mesothelioma, Malignant |
| D054363 | Solitary Fibrous Tumor, Pleural |
| ID | Term |
|---|---|
| D008654 | Mesothelioma |
| D000236 | Adenoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D018301 | Neoplasms, Mesothelial |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D010997 | Pleural Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D054364 | Solitary Fibrous Tumors |
| D018218 | Neoplasms, Fibrous Tissue |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
Not provided
Not provided
| ID | Term |
|---|---|
| D007124 | Immunoenzyme Techniques |
| ID | Term |
|---|---|
| D007118 | Immunoassay |
| D007158 | Immunologic Techniques |
| D008919 | Investigative Techniques |
| D007150 | Immunohistochemistry |
| D015336 | Molecular Probe Techniques |
Not provided
Not provided